
Enanta Pharmaceuticals (NASDAQ:ENTA) focuses on discovering, developing, and commercializing small molecule drugs for the treatment of viral infections and liver diseases. Specializing in creating treatments for respiratory syncytial virus, hepatitis B virus, and human metapneumovirus, Enanta is committed to addressing unmet medical needs. Their projects range from preclinical to phase 2 development, showcasing their comprehensive approach to tackling complex diseases. With objectives centered around innovation, patient health, and expanding their pipeline of therapeutic candidates, Enanta aims to be at the forefront of transformative treatment solutions.